- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03215381
AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers
February 23, 2018 updated by: AstraZeneca
An Open-Label Positron-Emission Tomography (PET) Study to Determine Brain Exposure of AZD1390 After Intravenous Administration of a Microdose [11C]AZD1390 to Healthy Volunteers
This is an open-label, single centre exploratory study to analyse brain exposure of AZD1390 in healthy volunteer males.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Up to 12 healthy male volunteers, 20 to 65 years of age will participate in the study.
The study population chosen is sufficient to examine variability in pharmacokinetic and imaging measurements.
All male volunteer subjects will have a baseline brain magnetic resonance imaging (MRI) for eligibility and anatomical delineation of brain regions to be applied in positron emission tomography (PET) image analysis.
An arterial line will be inserted on day the healthy volunteer arrives for the administration of study drug and PET imaging (Day 1).
The arterial line will be placed in the opposite arm than the one being used to administer the single intravenous microdose of [11C]AZD1390.
Blood samples will be collected after the administration of microdose [11C]AZD1390 bolus injection and during the PET imaging procedure.
The arterial line will be removed at the conclusion of the PET imaging study after the last blood sample has been collected.
Standard institutional procedures will be followed for arterial line removal.
The study will conclude with a telephone follow-up call within 7 business days after the PET measurement.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, 171 76
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures.
- Healthy Male subjects, aged 20 to 65 years (inclusive).
- Subject should be healthy as determined by medical history, physical examination, laboratory parameters, ECG and brain MRI performed before administration of the investigational product.
- Subject should have a body mass index (BMI) between 18.0 and 30.0 kg/m2 and must weigh at least 50.0 kg and no more than 100.0 kg.
- Male subjects must be willing to adhere to true sexual abstinence or use condoms and spermicide (refer to Section 4.3); and refrain from donating sperm during the study and for 3 months plus 5 half-lives after the last administered radiolabelled infusion of [11C]AZD1390.
- Subject should be willing and able to participate in all scheduled evaluations, abide by study restrictions, and complete all required tests and procedures.
Exclusion criteria:
- Known or suspected neurological or behavioural disorders or symptoms that may interfere with the conduct or interpretation of the study, dementia (significant concomitant neurological disease are included under this category).
- Current significant major or unstable respiratory, heart, cerebrovascular, haematological, hepatic, renal, gastrointestinal diseases, or other major disease.
- Suffers from claustrophobia that limits the ability to undergo the scanning procedure.
- Subject has implanted metal devices or implants (MRI contraindications).
- Subject has received any concomitant medication or herbal medicine within 2 weeks prior to study drug administration.
- Subject has a negative Allen test in both hands at screening, unless brachial artery is used for arterial cannulation.
- Use of any anticoagulant within 30 days prior to study drug administration.
- Subject has previously participated in a PET imaging study.
- Central nervous system infarct, infection or focal lesions of clinical significance on brain MRI scan or abnormalities observed on the brain MRI that would interfere with image analysis
- As judged by the investigator, subject with unstable hypertension or symptomatic hypotension, history of pre-syncope or syncope due to orthostatic hypotension and/or induced by change of posture (orthostatic hypotension defined as 25 mmHg decrease in systolic and/or 15 mmHg).
- Presence of significant abnormalities on physical and neurological clinical examinations, vital signs, ECG and clinical chemistry, haematology, or urine analysis results at screening that may interfere with the study or present a safety risk to the study subject.
- History or positive results for a systemic infection (e.g. hepatitis B virus, hepatitis C virus, HIV, tuberculosis), including previous or on-going infectious or autoimmune disease at screening.
- History of alcohol or drug abuse or dependence (except nicotine) within 1 year prior to screening and/or urine drug screen positive for drug abuse.
- Prolonged QTcF >450 ms or family history of long QT syndrome.
- History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to [11C]AZD1390.
- Judgment by the investigator of any other reason that would prohibit the inclusion of the subject in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: [11C]AZD1390 Microdose
[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
|
[11C]AZD1390
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain distribution of AZD1390
Time Frame: up to 2 hours post dose
|
To assess if 11C AZD1390 crosses the blood brain barrier in healthy volunteers
|
up to 2 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 10, 2017
Primary Completion (ACTUAL)
February 19, 2018
Study Completion (ACTUAL)
February 19, 2018
Study Registration Dates
First Submitted
June 29, 2017
First Submitted That Met QC Criteria
July 10, 2017
First Posted (ACTUAL)
July 12, 2017
Study Record Updates
Last Update Posted (ACTUAL)
February 26, 2018
Last Update Submitted That Met QC Criteria
February 23, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- D6940C00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer Male Subjects
-
Bioblast Pharma Ltd.ParexelCompletedHealthy Volunteer SubjectsUnited States
-
CelgeneCompletedSafety and Pharmacokinetics in Healthy Volunteer SubjectsUnited States
-
Yuhan CorporationCompletedHealthy Male VolunteerKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHealthy Male VolunteerKorea, Republic of
-
Janssen Research & Development, LLCCompleted
-
AkesoNot yet recruitingHealthy Male Subjects
-
Sunshine Lake Pharma Co., Ltd.Completed
-
RAPT Therapeutics, Inc.Completed
-
AstraZenecaParexelCompletedHealthy Male SubjectsUnited States
Clinical Trials on [11C]AZD1390
-
Nader SanaiAstraZeneca; Barrow Neurological Institute; Ivy Brain Tumor CenterRecruitingGlioma | Glioblastoma | Glioblastoma Multiforme | Glioma, MalignantUnited States
-
The Netherlands Cancer InstituteLeiden University Medical Center; University Medical Center NijmegenRecruitingSoft Tissue Sarcoma AdultNetherlands
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingSolid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic TumorUnited States
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
AstraZenecaRecruitingRecurrent Glioblastoma Multiforme | Brain Neoplasms, Malignant | Primary Glioblastoma Multiforme | Leptomeningeal Disease (LMD)United States, United Kingdom
-
Columbia UniversityCompleted
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Completed
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States